Please login to the form below

Not currently logged in


This page shows the latest MK-1775 news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

These include licensing the WEE1 inhibitor MK-1775 from Merck &Co, the $500m buyout of biotech Amplimmune and its portfolio of cancer antibodies, an alliance with the UK biotech Immunocore via

Latest news

  • AZ licenses Merck ovarian cancer drug AZ licenses Merck ovarian cancer drug

    Pays $50m upfront for MK-1775. AstraZeneca (AZ) has continued its pipeline-boosting shopping spree with a $50m upfront payment to Merck &Co for rights to a cancer drug in phase ... AZ will be responsible for all future clinical development, manufacturing,

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    Fostering partnerships. Recent developments include agreements to license the WEE1 inhibitor MK-1775 from Merck &Co and a collaboration with Bind Therapeutics which puts a molecule discovered by AZ – an Aurora

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Licence. Diagnostic products IVD. 75. Merck &Co / AstraZeneca. Licence. WEE1 kinase (MK-1775) for ovarian cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    Another oncology deal of note was AstraZeneca's(AZ) licence of Merck &Co's WEE1 kinase (MK-1775) currently being evaluated in phase IIa clinical studies in combination with standard of ... death. Preclinical evidence suggests that the combination of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...